Clinical trial NCT01867463 - References

Malaria — Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine

Citation(s)

•   Diallo M, Touré AM, Traoré SF, Niaré O, Kassambara L, Konaré A, Coulibaly M, Bagayogo M, Beier JC, Sakai RK, Touré YT, Doumbo OK
  Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. Malar J. 2008 Dec 2;7:248. doi: 10.1186/1475-2875-7-248.
•   Kaslow DC
  Transmission-blocking vaccines. Chem Immunol. 2002;80:287-307. Review.
•   Williamson KC, Keister DB, Muratova O, Kaslow DC
  Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol. 1995 Dec;75(1):33-42.

Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali

Details for clinical trial NCT01867463